Parental obesity and risk of metabolic dysfunction associated steatotic liver disease in adult offspring: UK birth cohort study: GI Signals

Hepatology prospective cohort · n=1,933 · Sep 7, 2026 · Gut · IF 24.6

Parental obesity and risk of metabolic dysfunction associated steatotic liver disease in adult offspring: UK birth cohort study.

EpidemiologyMASLDepidemiologyobesity

Clinical takeawayParental obesity predicts offspring MASLD risk through cumulative childhood weight gain (67% of effect). In counseling, frame childhood weight management as potentially protective and modifiable, even with obese parents. No new screening, testing, or treatment for MASLD is directly supported by this observational association study.

What it foundEach 1 kg/m2 increase in maternal pre-pregnancy BMI raised offspring MASLD odds by 10% (OR 1.10, 95% CI 1.06-1.14); paternal BMI increase raised odds by 9% (OR 1.09, 95% CI 1.04-1.13). Both parents overweight or obese associated with 3.73-fold increased odds of offspring MASLD at age 24 (95% CI 2.43-5.73 vs. normal-BMI parents), with 67% of this association mediated by cumulative excess childhood BMI (area under the curve for BMI Z-score >1, ages 7-17).

ContextMaternal obesity → offspring metabolic disease is established; this adds paternal obesity (similar effect size) and clarifies the transmission pathway. The key refinement is that cumulative childhood BMI mediates 67% of the parental obesity association, suggesting childhood weight management (rather than accepting genetic predisposition) is modifiable. MASLD prevalence at age 24 (10.4%) reflects its epidemiologic dominance.

Emergingsuggested applicable standard· AASLD 2023 Practice Guidance, updated by AASLD Practice Guidance October 2024 (resmetirom) and November 2025 (semaglutide)

Decision at stakeidentifying and counseling high-risk offspring of obese parents for early MASLD prevention through sustained weight management across childhood and adolescence

Diagnose MASLD by hepatic steatosis on imaging (or biopsy) plus at least one cardiometabolic criterion and exclusion of competing etiologies (significant alcohol use, other liver disease), then risk-stratify fibrosis using a sequential non-invasive approach: FIB-4 first, followed by a second-line imaging-based test (VCTE, MRE, or ELF) for indeterminate/high-risk FIB-4, with liver biopsy reserved for discordant or unclear cases. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose MASLD by hepatic steatosis on imaging (or biopsy) plus at least one cardiometabolic criterion and exclusion of competing etiologies (significant alcohol use, other liver disease), then risk-stratify fibrosis using a sequential non-invasive approach: FIB-4 first, followed by a second-line imaging-based test (VCTE, MRE, or ELF) for indeterminate/high-risk FIB-4, with liver biopsy reserved for discordant or unclear cases. Lifestyle modification (≥7-10% weight loss, Mediterranean diet, exercise) remains the foundation for all patients. For adults with MASH and F2-F3 fibrosis identified by non-invasive tests (VCTE 8-15 kPa, MRE 3.1-4.4 kPa, or ELF 9.2-10.5) rather than biopsy, AASLD now gives dedicated, updated practice guidance on both FDA-approved pharmacotherapies: resmetirom (Oct 2024 update) and semaglutide 2.4mg/week subcutaneous (Nov 2025 update, following August 2025 accelerated FDA approval based on ESSENCE trial data: 62.9% vs 34.3% MASH resolution without fibrosis worsening; 36.8% vs 22.4% ≥1-stage fibrosis improvement). Pioglitazone or vitamin E remain options per the 2023 base guidance. Manage cardiometabolic risk with statins for ASCVD reduction plus glycemic and blood-pressure control; for semaglutide specifically, routine hepatic panels are recommended only as clinically indicated (no discontinuations for LFT elevation in ESSENCE), with monitoring for GI adverse effects and rare risks (AKI, gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, lean mass loss). HCC surveillance with ultrasound and AFP every 6 months remains indicated only if cirrhosis is present.

AASLD 2023 Practice Guidance, updated by AASLD Practice Guidance October 2024 (resmetirom) and November 2025 (semaglutide) · reviewed 2026-07-23 ↗

Tica S … Cao Y · Gut · IF 24.6 · PubMed ↗Permalink